This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

Educational information

This educational video is the second part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Other topics covered in this series

Other lectures part of this educational series are:

• Identifying patients for PCSK9 therapy - Prof. Kees Hovingh, MD, Amsterdam University Medical Center , The Netherlands
• Landmark trials with PCSK9 inhibitors - Prof. Gabriel Steg, MD, Hôpital Bichat, Paris, France
• Guidelines and the role of non-statin therapies for high risk ASCVD patients - Prof. Wouter Jukema, MD, Leiden University Medical Center, The Netherlands

Faculty

John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France.

CME Accreditation

This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section

Disclosures

This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.

View slides of prof. Chapman